Multiple Sclerosis: Expanded Treatment Options Improve Outcomes for a Disabling Chronic Condition

Therapeutic advances over the past decade have offered MS patients more convenient options with improved treatment outcomes.

MS affects more than 400,000 Americans and 2.3 million people worldwide. While there is currently no cure for the disease, advances in treatment over the last decade have produced an arsenal of new medicines to slow disease progression, prevent relapses, and more effectively manage symptoms. Many of these medicines provide greater convenience and fewer side effects, while also providing alternatives to meet the diverse needs of people with MS, thereby supporting successful overall disease management.

Today there are 40 medicines in development to treat MS, offering even greater opportunity to transform the landscape of treatment. Researchers continue to focus on meeting the unmet needs of patients with the progressive form of MS, who presently lack available treatment options. Experimental antibody medicines targeting a protein involved in MS which inhibits the production of myelin are among the innovative approaches demonstrating significant potential for MS patients—including those with the progressive form of the disease. Remarkable progress has been made over the past decade, but research and development continues to provide hope for patients struggling with this diverse and debilitating chronic disease.